| Literature DB >> 35433852 |
Xi Yang Zhou1,2, Chun Xiang Tang2, Ying Kun Guo3, Xin Wei Tao4, Wen Cui Chen5, Jin Zhou Guo5, Gui Sheng Ren5, Xiao Li6, Song Luo2, Jun Hao Li1,2, Wei Wei Huang2, Guang Ming Lu2, Long Jiang Zhang2, Xiang Hua Huang4, Yi Ning Wang6, Gui Fen Yang1.
Abstract
Objectives: To assess the potential of a radiomics approach of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) in the diagnosis of cardiac amyloidosis (CA). Materials andEntities:
Keywords: cardiac amyloidosis; cardiac magnetic resonance imaging; diagnostic performance; late gadolinium enhancement; radiomics
Year: 2022 PMID: 35433852 PMCID: PMC9005767 DOI: 10.3389/fcvm.2022.818957
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1The flowchart of this study. CA, cardiac amyloidosis; AL, light chain amyloidosis; ASCT, autologous stem cell transplant; A center, the Second West China Hospital, Sichuan University, China; B center, Peking Union Medical College Hospital, China.
Clinical characteristics and cardiac magnetic resonance (CMR) data in the training and validation data sets.
| Variables | Internal cohort ( | External cohort ( | ||||
|
|
| |||||
| All ( | Training set ( | Validation set ( | Validation set ( | |||
|
| ||||||
| Male, | 75 (53.9) | 54 (55.7) | 21 (50.0) | 0.538 | 42 (68.9) | |
| Age, years | 53.8 ± 8.4 | 52.9 ± 8.4 | 55.7 ± 8.1 | 0.077 | 60 ± 9.2 | <0.001 |
|
| ||||||
| Hypertension | 25 (18) | 13 (13.4) | 12 (28.6) | 0.032 | 5 (8.2) | 0.074 |
| Hyperlipidemia | 45 (32.4) | 32 (33.0) | 13 (31.0) | 0.814 | 7 (11.5) | 0.008 |
| Diabetes mellitus | 10 (7.2) | 8 (8.3) | 2 (4.8) | 0.465 | 7 (11.5) | 0.535 |
| Coronary disease | 3 (2.2) | 2 (2.1) | 1 (2.4) | 0.905 | 0 | 0.248 |
|
| ||||||
| Troponin T, ng/mL | 0.02 (0.01, 0.04) | 0.02 (0.01, 0.04) | 0.02 (0.01, 0.03) | 0.801 | 0.066 (0.017, 0.163) | <0.001 |
| NT-proBNP, pg/mL | 274 (102, 1,682) | 227 (95.7, 1,645) | 543 (121, 1,438) | 0.491 | 2,423 (308, 5,253) | <0.001 |
| Positive CA, | 79 (56.8) | 51 (52.6) | 28 (66.7) | 0.124 | 41 (67.2) | 0.168 |
| Mayo stage (I/II/III/IV) | 78/29/26/6 | 50/21/17/4 | 23/8/9/2 | 0.129 | 18/8/26/9 | <0.001 |
|
| ||||||
| LVEF, % | 63.9 (55.5, 70.0) | 64.5 (55.6, 70.2) | 64.5 (55.1, 70.1) | 0.984 | 50.8 ± 12.4 | <0.001 |
| LVEDV, ml | 99.7 (87.2, 117.3) | 99.5 (87.5, 117) | 101 (88.7, 117) | 0.489 | 123 (106, 149) | <0.001 |
| LVESV, ml | 36.1 (26.8, 46.5) | 35.8 (26.7, 46.3) | 37.2 (27.3, 49.4) | 0.785 | 54.0 (45.8, 79.3) | <0.001 |
|
| ||||||
| Total enhanced volume, ml | 9.1 (1.8, 25.0) | 8.7 (1.93, 20.0) | 15.0 (1.81, 40.9) | 0.236 | 5.6 (1.8, 19.1) | 0.209 |
| Total enhanced mass, ml | 9.6 (1.9, 26.3) | 9.1 (2.0, 21.0) | 15.8 (1.9, 42.9) | 0.236 | 5.9 (1.9, 20.1) | 0.209 |
| LGE extent, % | 15.9 (4.7, 36.6) | 16.6 (4.9, 37.9) | 14.3 (2.5, 36.5) | 0.288 | 9.8 (2.7, 26.6) | 0.041 |
Data given as mean ± standard deviation (SD), n (%), or median (interquartile range).
NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricle ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricle end-systolic volume; LGE, late gadolinium enhancement.
FIGURE 2Feature importance of radiomics. The figure shows the feature importance of global (A), basal (B), mid (C), and apical (D) radiomics signature. Different colors represent different clusters.
FIGURE 3Heatmap of the 10 most relevant radiomics features of global myocardium for differentiating cardiac amyloidosis (CA) from non-CA patients. 0 represents the patients without CA, while 1 represents positive CA patients.
FIGURE 4Workflow of the development and validation of radiomics model. First, lesions are manually segmented on late gadolinium enhancement (LGE) MR images for radiomics analysis. Second, a total of 1,906 radiomics features are extracted on global myocardium and three different sections (base, mid-cavity, and apex), respectively. Third, in the training phase, Boruta algorithm is used for feature selection. Fourth, XGBoost machine learning algorithm is used for model building. Finally, in the validation phase, the model is tested in the internal data set and external data sets.
The performance of radiomics model in the training, internal, and external validation data sets.
| Accuracy (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | AUC (95% CI) | |
|
| ||||||
| Training | 0.78 (0.69–0.86) | 0.82 (0.69–0.92) | 0.83 (0.69–0.92) | 0.84 (0.73–0.91) | 0.81 (0.70–0.89) | 0.89 (0.83–0.95) |
| Internal | 0.82 (0.73–0.89) | 0.96 (0.82–1.00) | 0.64 (0.35–0.87) | 0.84 (0.73–0.92) | 0.90 (0.56–0.99) | 0.89 (0.78–1.00) |
| External | 0.81 (0.66–0.91) | 0.93 (0.80–0.99) | 0.75 (0.51–0.91) | 0.88 (0.78–0.94) | 0.83 (0.62–0.94) | 0.92 (0.85–0.98) |
|
| ||||||
| Training | 0.86 (0.77–0.92) | 0.86 (0.74–0.94) | 0.84 (0.71–0.94) | 0.86 (0.76–0.93) | 0.85 (0.74–0.92) | 0.92 (0.86–0.97) |
| Internal | 0.81 (0.66–0.91) | 0.79 (0.59–0.92) | 0.86 (0.57–0.98) | 0.92 (0.75–0.98) | 0.67 (0.49–0.81) | 0.89 (0.79–0.99) |
| External | 0.87 (0.76–0.94) | 0.90 (0.77–0.97) | 0.80 (0.56–0.94) | 0.90 (0.79–0.96) | 0.80 (0.61–0.91) | 0.92 (0.85–0.99) |
|
| ||||||
| Training | 0.82 (0.73–0.89) | 0.84 (0.71–0.93) | 0.80 (0.66–0.91) | 0.83 (0.72–0.90) | 0.82 (0.71–0.90) | 0.89 (0.82–0.95) |
| Internal | 0.86 (0.81–0.95) | 0.93 (0.77–0.99) | 0.71 (0.42–0.92) | 0.87 (0.74–0.94) | 0.83 (0.56–0.95) | 0.87 (0.76–0.98) |
| External | 0.85 (0.74–0.93) | 0.90 (0.77–0.97) | 0.95 (0.75–1.00) | 0.97 (0.85–1.00) | 0.83 (0.65–0.92) | 0.92 (0.84–0.99) |
|
| ||||||
| Training | 0.80 (0.71–0.88) | 0.78 (0.65–0.89) | 0.83 (0.69–0.92) | 0.83 (0.72–0.91) | 0.78 (0.67–0.86) | 0.87 (0.80–0.94) |
| Internal | 0.81 (0.66–0.91) | 0.93 (0.77–0.99) | 0.64 (0.35–0.87) | 0.84 (0.72–0.91) | 0.82 (0.53–0.95) | 0.87 (0.74–1.00) |
| External | 0.84 (0.72–0.92) | 0.90 (0.77–0.97) | 0.70 (0.46–0.88) | 0.86 (0.76–0.92) | 0.78 (0.57–0.90) | 0.90 (0.83–0.98) |
PPV, positive predictive value; NPV, negative predictive value.
FIGURE 5Receiver operating characteristic (ROC) curves analysis for comparison of diagnostic performance of radiomics with qualitative and quantitative LGE assessment. Basal radiomics vs. qualitative (LGE pattern), semiquantitative (QALE score), and quantitative (based on cardiac magnetic resonance (CMR) software) assessment parameters in the training (A), internal (B), and external validation (C) cohorts. QALE, query amyloid late enhancement.
Diagnostic performance of qualitative, semiquantitative, and quantitative parameters in cardiac amyloidosis (CA).
| Internal data ( | External Data ( | ||||||
|
|
| ||||||
| Training cohort ( | Validation cohort ( | External cohort ( | |||||
|
|
|
| |||||
| Variables | AUC (95% CI) | AUC (95% CI) | AUC (95% CI) | ||||
| Qualitative | LGE (±) | 0.80 (0.72–0.88) | 0.003 | 0.75 (0.61–0.89) | 0.022 | 0.79 (0.68–0.90) | 0.008 |
| Semiquantitative | QALE score | 0.85 (0.77–0.92) | 0.073 | 0.80 (0.69–0.92) | 0.144 | 0.86 (0.78–0.94) | 0.123 |
| Quantitative | Total enhanced volume, ml | 0.80 (0.71–0.89) | 0.009 | 0.88 (0.78–0.99) | 0.885 | 0.67 (0.53–0.81) | <0.001 |
| Total enhanced mass, g | 0.80 (0.71–0.89) | 0.009 | 0.88 (0.78–0.99) | 0.885 | 0.67 (0.53–0.81) | <0.001 | |
| Enhanced volume (%) | 0.76 (0.66–0.85) | 0.002 | 0.88 (0.77–0.99) | 0.872 | 0.63 (0.49–0.78) | <0.001 | |
| Radiomics | Basal Rad score | 0.92 (0.86–0.97) | 0.89 (0.79–0.99) | 0.92 (0.85–0.99) | |||
AUC, area under curve; QALE, Query Amyloid Late Enhancement; Rad-score, radiomics score.